Lv53
1100 积分 2024-04-25 加入
JAK inhibitors for the treatment of autoimmune and inflammatory diseases
1个月前
已完结
A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases
2个月前
已完结
652 | EFFECTIVENESS AND SAFETY OF POLA‐R‐CHP REGIMEN IN PREVIOUSLY UNTREATED LOW‐RISK DLBCL: A NATIONWIDE MULTICENTER RETROSPECTIVE STUDY OF IPI 0–1 PATIENTS IN CHINA
2个月前
已完结
Abemaciclib: The First FDA-Approved CDK4/6 Inhibitor for the Adjuvant Treatment of HR+ HER2− Early Breast Cancer
2个月前
已完结
Analysis of Predictive Factors for Early Response to Ruxolitinib in 320 Patients with Myelofibrosis From the Polish Adult Leukemia Group (PALG) Registry
2个月前
已完结
From Palliation to Targeted Therapy in Myelofibrosis
2个月前
已完结
The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis
2个月前
已完结
How I Treat Anemia in Myelofibrosis
2个月前
已完结
Momelotinib for the treatment of myelofibrosis with anemia
2个月前
已完结
Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study
2个月前
已完结
皖公网安备34019202002308
